ScholarIQanswers from OpenAlex & ORCID
Luca Arcaini
ResearcherPublications, citations & collaboration network
Luca Arcaini is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Luca Arcaini have?
ScholarIQindexed works
Luca Arcaini has 584 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Luca Arcaini have?
ScholarIQcitation count
Luca Arcaini has 21,225 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Luca Arcaini?
ScholarIQh-index
Luca Arcaini has an h-index of 72 in OpenAlex.
What is the i10-index of Luca Arcaini?
ScholarIQi10-index
Luca Arcaini has an i10-index of 210 in OpenAlex.
What is the ORCID of Luca Arcaini?
ScholarIQorcid
The ORCID for Luca Arcaini is on the source record.
What is the OpenAlex record for Luca Arcaini?
ScholarIQopenalex
The OpenAlex for Luca Arcaini is on the source record.
What are the most-cited papers on Luca Arcaini?
ScholarIQmost cited works
Follicular Lymphoma International Prognostic Index 2: A New Prognostic Index for Follicular Lymphoma Developed by the International Follicular Lymphoma Prognostic Factor Project
Massimo Federico, Monica Bellei, Luigi Marcheselli, Stefano Luminari, Armando López‐Guillermo, Umberto Vitolo, Barbara Pro, Stefano Pileri, Alessandro Pulsoni, Pierre Soubeyran, Sergio Cortelazzo, Giovanni Martinelli, Maurizio Martelli, Luigi Rigacci, Luca Arcaini, Francesco Di Raimondo, Francesco Merli, Elena Sabattini, Peter McLaughlin, Philippe Solal‐Céligny
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
Steven M. Horwitz, Owen A. O’Connor, Barbara Pro, Tim Illidge, Michelle A. Fanale, Ranjana H. Advani, Nancy L. Bartlett, Jacob Haaber Christensen, Franck Morschhauser, Eva Domingo‐Doménech, Giuseppe Rossi, Won Seog Kim, Tatyana Feldman, Anne Lennard, David Belada, Árpád Illés, Kensei Tobinai, Kunihiro Tsukasaki, Su‐Peng Yeh, Andrei R. Shustov, Andreas Hüttmann, Kerry J. Savage, Sam Yuen, Swaminathan P. Iyer, Pier Luigi Zinzani, Zhaowei Hua, Meredith Little, Shangbang Rao, Joseph Woolery, Thomas Manley, Lorenz Trümper, David M. Aboulafia, Ranjana H. Advani, Önder Alpdoğan, Kiyoshi Ando, Luca Arcaini, Luca Baldini, Naresh Bellam, Nancy L. Bartlett, David Belada, Dina Ben Yehuda, Fabio Benedetti, Peter Borchman, Dominique Bordessoule, Pauline Brice, Javier Briones, Dolores Caballero, Angelo Michele Carella, Hung Chang, June Weon Cheong, Seok‐Goo Cho, Ilseung Choi, Sylvain Choquet, Andrei Coliţă, Angela Giovanna Congui, Francesco d’Amore, Nam H. Dang, Kelly Davison, Sophie de Guibert, Peter de Nully Brown, Vincent Delwail, Judit Demeter, Francesco Di Raimondo, Young Rok, Eva Domingo, Michael G. Douvas, Martin Dreyling, Thomas Ernst, Michelle A. Fanale, Keith Fay, Tatyana Feldman, Silvia Ferrero, Ian W. Flinn, Andres Forero‐Torres, Christopher P. Fox, Jonathan W. Friedberg, Noriko Fukuhara, José A. García‐Marco, Jorge Gayoso Cruz, José Codina, Rémy Gressin, Andrew Grigg, Ronit Gurion, Jacob Haaber Christensen, Corinne Haïoun, Roman Hájek, Mathias Hänel, Kiyohiko Hatake, Robert Hensen, Netanel A. Horowitz, Steven M. Horwitz, Andreas Hüttmann, Árpád Illés, Tim Illidge, Kenichi Ishizawa, Miguel Islas‐Ohlmayer, Eric D. Jacobsen, Murali Janakiram, Wojciech Jurczak, Mark Kaminski
R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Follicular Lymphoma: Results of the FOLL05 Trial Conducted by the Fondazione Italiana Linfomi
Massimo Federico, Stefano Luminari, Alessandra Dondi, Alessandra Tucci, Umberto Vitolo, Luigi Rigacci, Francesco Di Raimondo, Angelo Michele Carella, Alessandro Pulsoni, Francesco Merli, Luca Arcaini, F. Angrilli, Caterina Stelitano, Gianluca Gaïdano, Matteo Dell’Olio, Luigi Marcheselli, Vito Franco, Sara Galimberti, Stefano Sacchi, Maura Brugiatelli